Misoprostol in the treatment of NSAID-induced gastroduodenal lesions.
dc.contributor.author | Ahmed, W U | en_US |
dc.contributor.author | Kirmani, S R | en_US |
dc.contributor.author | Qureshi, H | en_US |
dc.contributor.author | Alam, S E | en_US |
dc.contributor.author | Zuberi, S J | en_US |
dc.date.accessioned | 1991-10-01 | en_US |
dc.date.accessioned | 2009-05-29T02:30:18Z | |
dc.date.available | 1991-10-01 | en_US |
dc.date.available | 2009-05-29T02:30:18Z | |
dc.date.issued | 1991-10-01 | en_US |
dc.description.abstract | The cytoprotective effect of misoprostol co-administered with non-steroidal anti-inflammatory drugs (NSAIDs) was assessed in a double blind, placebo controlled study. Thirty-seven patients with rheumatoid arthritis receiving NSAIDs, having upper gastrointestinal symptoms and endoscopically confirmed gastric and/or duodenal lesions, were randomised to receive either misoprostol 200 micrograms or placebo tablets twice daily for 4 weeks. Of 31 evaluable cases, 13 of 16 (81%) patients receiving misoprostol showed endoscopic improvement as compared to 10 of 15 (67%) receiving placebo (P:NS). A significant decrease in mean (+/- SEM) mucosal lesion score was observed with misoprostol (from 3.38 +/- 0.32 to 1.32 +/- 0.44; P less than 0.001) but no change was seen with placebo (from 2.80 +/- 0.42 to 1.60 +/- 0.53; P:NS). Symptomatic relief was similar in both groups, being 44% and 40% respectively. Two patients complained of diarrhea in each group and one developed menorrhagia with misoprostol. It is concluded that though misoprostol decreased the number of NSAID-induced mucosal lesions, it was unable to relieve gastrointestinal symptoms. | en_US |
dc.description.affiliation | Research Centre, Jinnah Postgraduate Medical Centre, Karachi, Pakistan. | en_US |
dc.identifier.citation | Ahmed WU, Kirmani SR, Qureshi H, Alam SE, Zuberi SJ. Misoprostol in the treatment of NSAID-induced gastroduodenal lesions. Indian Journal of Gastroenterology. 1991 Oct; 10(4): 135-6 | en_US |
dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/64222 | |
dc.language.iso | eng | en_US |
dc.source.uri | https://www.indianjgastro.com | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Anti-Inflammatory Agents, Non-Steroidal --adverse effects | en_US |
dc.subject.mesh | Arthritis, Rheumatoid --drug therapy | en_US |
dc.subject.mesh | Double-Blind Method | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Gastrointestinal Diseases --chemically induced | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Misoprostol --therapeutic use | en_US |
dc.title | Misoprostol in the treatment of NSAID-induced gastroduodenal lesions. | en_US |
dc.type | Clinical Trial | en_US |
dc.type | Journal Article | en_US |
dc.type | Randomized Controlled Trial | en_US |
Files
License bundle
1 - 1 of 1